Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 14,161 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone; Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: IONIS-AGT-LRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Little Rock, Arkansas • Crystal River, Florida • Hialeah, Florida + 6 more

Conditions: HIV Infections
Interventions: WT-gag-TCR modified T cells, α/6-gag-TCR modified T cells, STI or Drug Holiday; Biological · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza -Like Illness
Interventions: Norketotifen, Placebo; Drug
Lead sponsor: Emergo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more

Conditions: Crohn's Disease
Interventions: Ontamalimab, Placebo; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 48
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 41 more

Conditions: Diabetes
Interventions: MBX-2982, Sitagliptin, placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Los Angeles, California • Las Vegas, Nevada • Binghamton, New York + 1 more

Conditions: Dyslipidaemias, Dyslipidemias
Interventions: GSK256073, Placebo, Niaspan; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more

Conditions: Bipolar I Disorder, Mania, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 46
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 39 more

Conditions: Healthy Participants Study
Interventions: AZD0292, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more

Conditions: Interstitial Cystitis
Interventions: LP-08 80mg, Normal saline, LP-08 20mg; Drug
Lead sponsor: Lipella Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hot Flashes, Prostate Cancer
Interventions: cyproterone acetate, quality-of-life assessment; Drug · Procedure
Lead sponsor: Barr Laboratories; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Pomona, New York

Conditions: Asthma
Interventions: Fluticasone propionate, Placebo, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more

Conditions: Asthma
Interventions: Placebo, Brodalumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 73
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more

Conditions: Healthy Subjects
Interventions: CKD-508 Tablet, Placebo Tablet; Drug
Lead sponsor: Chong Kun Dang Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Essential Tremor of the Upper Limbs
Interventions: IncobotulinumtoxinA, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Furunculosis
Interventions: Antimicrobial TheraGauze; Biological
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Erectile Dysfunction
Interventions: Placebo, One POMx capsule daily, 2 POMx Capsules; Drug
Lead sponsor: POM Wonderful LLC; Industry
Eligibility: 21 Years to 70 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Parkinson's Disease, Movement Disorder Syndrome
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Home Care for Elderly or Disabled Individuals
Interventions: IHSS Basic Training; Other
Lead sponsor: Abdul Latif Jameel Poverty Action Lab; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Bernardino, California

Conditions: Unspecified Child Maltreatment, Suspected, Unspecified Child Maltreatment, Confirmed
Interventions: Durham Connects; Other
Lead sponsor: Duke University; Other
Eligibility: Up to 6 Months
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions: HEPLISAV-B®; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more

Conditions: HIV Infections
Interventions: Recombinant human interleukin-7; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • Chicago, Illinois + 1 more

Search by objective public record fields.

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

Study to Test GSK256073 in Patients With Dyslipidemia

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome

Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

Botulinum Toxin A to Treat Arm Tremor

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess

POMx In the Treatment of Erectile Dysfunction

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Evaluating the Impact of Training for IHSS Workers

Durham Connects RCT Evaluation II

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs